Final Analysis of Efficacy and Safety of Single-Dose Ad26.COV2.S.
PMID: 35139271
2022
The New England journal of medicine
5Result: Vaccine efficacy against severe-critical Covid-19 was 93.1% (95% CI, 54.4 to 99.8) for the reference strain; 71.8% (95% CI, 56.3 to 82.3) for non-reference strain SARS-CoV-2 lineages, including ""other"" sequences with the E484K mutation; 78.4% (95% CI, 34.5 to 94.7) for the beta variant; 63.6% (95% CI, 18.8 to 85.1) for the gamma variant; 67.6% (95% CI, -29.8 to 94.4) for the lambda variant; and 79
8Discussion: Efficacy against severe-critical disease remained higher (74.6%) than efficacy against moderate to severe-critical disease, with a lower point estimate for variants (93.1% efficacy against the reference strain and 71.8% efficacy against non-reference strain lineages, including ""other"" sequences with the E484K mutation), indicating that Ad26.COV2.S induces higher levels of protection in proportion to the severity of the disease and the nature of the viral mutation."
Prolonged SARS-CoV-2 RNA shedding in a young man recovering from traumatic pneumothorax.
Abstract: Genotyping revealed canonical beta-variant E484K and N501Y mutations at earlier time points.
SARS-CoV-2 infections in mRNA vaccinated individuals are biased for viruses encoding spike E484K and associated with reduced infectious virus loads that correlate with respiratory antiviral IgG levels.
Abstract: E484K has rapidly emerged and has frequently been detected in several SARS-CoV-2 variants of concern.
Abstract: In this study, we review the epidemiology and impact of E484K, its effects on neutralizing effect of several monoclonal antibodies, convalescent plasma, and post-vaccine sera.
Conclusion: E484K can be selected when a culture recombinant virus expressing SARS-CoV-2 S is treated with antibody cocktails, and new variants with novel mutations are on the rise.
Conclusion: E484K escapes the neutralizing effect of several monoclonal antibodies, convalescent plas
Conclusion: An in vitro analysis of post-vaccination sera from different vaccines simultaneously showed significantly decreased activity against the variants of concern containing E484K.
In silico analysis of mutant epitopes in new SARS-CoV-2 lineages suggest global enhanced CD8+ T cell reactivity and also signs of immune response escape.
PMID: 35149224
2022
Infection, genetics and evolution
Abstract: Moreover, individual mutations such as Spike N501Y and Nucleocapsid D138Y were predicted to have an overall stronger affinity through HLA-I than the reference sequence while Spike E484K shows signs of evasion.
Result: In contrast, peptides derived from E484K exhibited weaker binding compared to the respective REF-derived peptides.
Table: E484K
Discussion: For instance, E484K substitution has overall less affinity to class I HLA molecules than the respective REF peptides, but no difference in antigenicity scores.
Discussion: On the other hand, 501Y substitution has a stronger affinity to the HLA alleles than the REF peptides but,
Conformational Flexibility and Local Frustration in the Functional States of the SARS-CoV-2 Spike B.1.1.7 and B.1.351 Variants: Mutation-Induced Allosteric Modulation Mechanism of Functional Dynamics and Protein Stability.
PMID: 35163572
2022
International journal of molecular sciences
Introduction: S-B.1.351 variant is characterized by 21 mutations with 9 mutations (L18F, D80A,
Method: A systematic mutational scanning and sensitivity analysis of the functional RBD residues (K417, E484, N501), S-B.1.1.7 mutational sites (N501Y, A570D, P681H, T716I, S982A, and D1118H) and S-B.1.351 mutational sites (L18F, D80A, D215G, K417N, E484K, N501Y, D614G, and A701V).
SARS-CoV-2 Variants Increase Kinetic Stability of Open Spike Conformations as an Evolutionary Strategy.
Result: 1C); E484K was later adopted by the Alpha variant after the emergence of the Beta and Gamma variants.
Result: E484K and N501Y reside in the RBM of spike that directly contacts the receptor hACE2.
Result: E484K substitution exhibited a noticeable effect of reducing the occupancy of ligand-free spike variant in the 0.5-FRET state and increasing the 0.3-FRET state occupancy.
Result: E484K-carrying SAlpha resides
Result: All three S variants, SAlpha (later strain), SBeta, and SGamma, share both N501Y and E484K substitutions.
Result: Analysis of hACE2-bound SAlpha+E484K.
Mass Screening of SARS-CoV-2 Variants using Sanger Sequencing Strategy in Hiroshima, Japan.
Abstract: Among 48 mutant isolates, 26 were B.1.1.7 (Alpha), 7 were E484K single mutation and the rest were other types of mutation.
Method: The initial checkpoint was set at nucleotide position nt23063 and if we found mutation from adenine (A) to thymine (T) at nt23063, further identification was done as follows: double mutation of A23063T (referred to N501Y) and C23271A (referred to A570D) for B.1.1.7 (Alpha), G23013A (referred to
Result: In April 2021, 65%, 29% and 6% were B.1.1.7 (Alpha), E484K mutations and other forms of mutation.
Result: In March 2021, 67% were B.1.1.7 (Alpha) and the rest were single E484K mutation.
Neutralizing antibody responses elicited by SARS-CoV-2 mRNA vaccination wane over time and are boosted by breakthrough infection.
PMID: 35166573
2022
Science translational medicine
Introduction: Another VOC to emerge at about the same time was Beta (B.1.351), which is characterized by other NTD mutations and deletions, as well as crucial RBD mutations, including K417N, E484K, and N501Y.
Structural basis for SARS-CoV-2 Delta variant recognition of ACE2 receptor and broadly neutralizing antibodies.
Result: In contrast, mutations in the Beta and Kappa S proteins, especially the E484K or E484Q substitution, may greatly impact RBM-targeting neutralizing MAbs.
Result: In fact, the RBM-targeting MAb 2H2 was greatly affected by the RBM mutations (K417N, E484K, and N501Y) in the Beta variant.
Result: Moreover, for 2H2, the other mutations, including K417N, E484K/Q, and N501Y mostly from the Beta and Kappa variants (N501Y also presented in the Alpha variant), all reside in its neutralizing epitopes on RBD.
Result: SARS-CoV-2 variants other than Delta harbor up to three distinct mutatio
Real-Time RT-PCR Allelic Discrimination Assay for Detection of N501Y Mutation in the Spike Protein of SARS-CoV-2 Associated with B.1.1.7 Variant of Concern.
Introduction: The E484K mutation has been observed in some B.1.1.7 genome sequences.
Introduction: This VOC has multiple mutations in the receptor-binding domain (RBD) of the S protein, including K417N, E484K, and N501Y.
Introduction: This VOC shares the S gene
Method: Clinical specimens that met these criteria with a CT value of <=30 underwent Sanger sequencing of a 698-bp (nucleotide positions 22516 to 23214) S gene fragment, which includes the locations of key receptor-binding domain (RBD) mutations (K417N/T, E484K, and N501Y).
SARS_CoV_2 mutation literature information.
PMID: 
2022
The New England journal of medicine
Browser Board
Co-occurred Entities
Filtrator
ViMRT